Abstract
Background This study evaluated the resilience and outcomes of maternal health services during the COVID-19 pandemic in two health facilities in eastern Sierra Leone. Its aims to describe the use of maternal healthcare services and maternal and neonatal outcomes in these two facilities before, during, and after the COVID-19 pandemic.
Methods The study involved analysis of routine programme data (March 2019 to February 2022) from two public-funded health facilities supported by a non-governmental organization (Partners In Health in Sierra Leone): Koidu Government Hospital and Wellbody Clinic. Aggregated and de-identified secondary data from the Partner In Health Maternal Health Database was abstracted using a standardized tool. Descriptive statistics and bivariable negative binomial regression were used to assess the association between time periods (before COVID-19 [March 2019 to February 2020], during COVID-19 emergency [March 2020 to February 2021], after COVID-19 emergency [March 2021 to February 2022) and outcomes each month (fourth antenatal care visit and facility deliveries).
Results The study analyzed 3,204 fourth antenatal care visits and 7,369 deliveries over 36 months at both health facilities. Fourth antenatal care visits (from 947 to 920) and facility deliveries (from 2309 to 2221) decreased during COVID-19 compared to pre-COVID-19. However, maternal (from 32 to 23) and neonatal (36 to 26) deaths declined during COVID-19 compared to the pre-COVID-19 period at Koidu Government Hospital.
Conclusion In Sierra Leone, the resources and efforts directed to the post-Ebola recovery strategy were tested during and after the COVID-19 pandemic. Our study demonstrates the resilience of maternal and neonatal services in two healthcare facilities in a less-affected region of Sierra Leone, to the anticipated disruptions due to the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Canadian Institute of Health Research (Funding Reference Number WI1-179883)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Sierra Leone Ethics and Scientific Review Committee with approval number 018/05/2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.